{"id":739975,"date":"2023-03-14T16:04:16","date_gmt":"2023-03-14T20:04:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/"},"modified":"2023-03-14T16:04:16","modified_gmt":"2023-03-14T20:04:16","slug":"adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/","title":{"rendered":"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN DIEGO, March  14, 2023  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1ZhHZNPyisvhSrzLl-kBku8Qg0xxG6OLNw4Adpq2FjITCHh3bOM0gYC0fQ5fYXa4G1ux9c0SBhLdO3GqlQNiLJp9ubzqCfvlhoyOu-h-0QU6AOglNix4tvXHKFbW1wut\" rel=\"nofollow noopener\" target=\"_blank\"><u>Adamis Pharmaceuticals Corporation<\/u><\/a> (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company\u2019s fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u1kQhWG516wgFbI84sr1HrS5Rf1WFhOMocDG0PkpxYlTSZxdwFFBqeRET4Mzju2OvakiQ5rYApOO-Gm2x16ykOHB01gFOV2UdsB_UjoSc5k=\" rel=\"nofollow noopener\" target=\"_blank\"><u>website<\/u><\/a>.\u00a0<\/p>\n<p>Event: Adamis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call\u00a0<br \/>Date: Thursday, March 16, 2023\u00a0<br \/>Time: 2:00 p.m. PT (5:00 p.m. ET)\u00a0<br \/>U.S. Dial-in (Toll Free): 1-877-423-9813\u00a0<br \/>Toll\/International Dial-in: 1-201-689-8573 \u00a0<\/p>\n<p>David J. Marguglio, President and CEO of Adamis, will host the call along with other members of the management team. The call is open to the public and will provide an update on recent developments, events that have taken place during the year, and certain goals for future periods. Forward-looking statements concerning expectations regarding future company performance may be made during the conference call.\u00a0<\/p>\n<p>A live audio webcast of the conference call will also be available via this <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=i8P00Tejwjm_Nl8RvPefbqBsFwjqe6i2TE4FW2Z9lTb63ME-8gFisM1W2d4KbkD6uyS3tVZqN6VigbdcwhHGJDu8bdlOjaZ968MmwBA8zevttWR4MSG1N1OysMp6doqz\" rel=\"nofollow noopener\" target=\"_blank\">link<\/a>, with a replay available shortly after the live event.\u00a0<\/p>\n<p>\n        <strong>About Adamis Pharmaceuticals<\/strong>\u00a0<\/p>\n<p>Adamis Pharmaceuticals Corporation\u00a0is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease. Company products approved by the FDA include <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-twMfn7vlqj3azc5LOMd4KHbVq5qBlxXLQQAfHDxb0zIQqz4g2eDok24_fgdT63a\" rel=\"nofollow noopener\" target=\"_blank\">ZIMHI<\/a><sup>\u00ae<\/sup>\u00a0(naloxone) Injection for the treatment of opioid overdose and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=hyh0DiWhRtS_eoN8ozz80uMojyF2ctlpoTl3XMvDqXcsOYd2wwnsKFw2EiCw_az7lSEWKudt23nsLFVWcJBkAw==\" rel=\"nofollow noopener\" target=\"_blank\">SYMJEPI<\/a><sup>\u00ae<\/sup>\u00a0(epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. For additional information about\u00a0Adamis Pharmaceuticals, please visit our\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=u1kQhWG516wgFbI84sr1HkPsqgTZf8v6RSUR7z3_G59oLLkVe0hLV06unvZzOwRPNJaU53afgeydxwLJxji-zGOChtHLtxnhCpfrZpSJq-E=\" rel=\"nofollow noopener\" target=\"_blank\">website<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZapaQs5m9mydhI-xoN02CJF8ypvfb_5KQPUapBt6qLaHbprUxunleTIRx14Sq4LjrocXb7dQS8Sqsuvlb_O3yA==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2teM8VhE95sBfBZ3IQ_zKTSJLw8oFNI3jCq6aO_4ZDlT95YCqMUeJ1USelGKrjXUTpkUTlDfgVXRvu8f39BF4kpwPizK7nqyEhs7_Olxbcdhj92RAVs1w_z498C02uq1TbFcZ6Kqb6UCJxHCNOfScw==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>. \u00a0\u00a0\u00a0<\/p>\n<p>\n        <strong>Contact:<\/strong>\u00a0<\/p>\n<p>Adamis Investor Relations\u00a0\u00a0<br \/>Robert Uhl\u00a0<br \/>Managing Director\u00a0<br \/>ICR Westwicke\u00a0\u00a0<br \/>619.228.5886\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xzTQcC6-KdFy_hdTUmFcK4fXOi_8Tngh6ZbSilG7ll0gqLuWMxKYXqjlkMfT7L5a324RHP1x785Jq4tu-zVwkbRWyLYHdngvCy8yFc7icr4=\" rel=\"nofollow noopener\" target=\"_blank\"><u>robert.uhl@westwicke.com<\/u><\/a><\/p>\n<p \/>\n      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTRlOGVkMDctNmRhYi00NTBkLTgyOTQtYjYwYWYyN2ZjYzJlLTEwMjg5MzI=\/tiny\/Adamis-Pharmaceuticals-Corpora.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) &#8212; Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company\u2019s fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its website.\u00a0 Event: Adamis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call\u00a0Date: Thursday, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-739975","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) &#8212; Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company\u2019s fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its website.\u00a0 Event: Adamis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call\u00a0Date: Thursday, &hellip; Continue reading &quot;Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-14T20:04:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update\",\"datePublished\":\"2023-03-14T20:04:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/\"},\"wordCount\":331,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/\",\"name\":\"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=\",\"datePublished\":\"2023-03-14T20:04:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Market Newsdesk","og_description":"SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) &#8212; Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a commercial-stage biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including opioid overdose, allergy, respiratory and inflammatory disease, today announced that it will host an investor conference call on Thursday, March 16, 2023 at 2:00 p.m. PT to discuss its financial and operating results for the fourth quarter and full year 2022 as well as provide a corporate update. The company\u2019s fourth quarter and full year 2022 financial results news release is expected to be available after 1 p.m. PT on March 16, 2023, and on its website.\u00a0 Event: Adamis Pharmaceuticals Fourth Quarter and Full Year 2022 Financial Results Conference Call\u00a0Date: Thursday, &hellip; Continue reading \"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-03-14T20:04:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update","datePublished":"2023-03-14T20:04:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/"},"wordCount":331,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/","name":"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=","datePublished":"2023-03-14T20:04:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc4ODI2MCM1NDYxOTE3IzIwMTczNTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adamis-pharmaceuticals-schedules-fourth-quarter-and-full-year-2022-financial-results-conference-call-and-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2022 Financial Results Conference Call and Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=739975"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/739975\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=739975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=739975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=739975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}